William Blair Comments on Incyte Co.’s Q2 2025 Earnings (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY) – Equities research analysts at William Blair cut their Q2 2025 earnings per share estimates for Incyte in a research note issued on Tuesday, April 23rd. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $1.19 for the quarter, down from their previous forecast of $1.23. William Blair has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $3.85 per share. William Blair also issued estimates for Incyte’s Q3 2025 earnings at $1.31 EPS and Q4 2025 earnings at $1.35 EPS.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, February 13th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, missing the consensus estimate of $1.15 by ($0.09). Incyte had a net margin of 16.17% and a return on equity of 12.56%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the business earned $0.44 earnings per share. Incyte’s quarterly revenue was up 9.3% on a year-over-year basis.

INCY has been the topic of a number of other reports. JMP Securities downgraded Incyte from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 14th. Oppenheimer decreased their target price on Incyte from $92.00 to $84.00 and set an “outperform” rating on the stock in a research report on Wednesday. Bank of America decreased their target price on Incyte from $69.00 to $67.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 13th. Truist Financial decreased their price objective on Incyte from $91.00 to $84.00 and set a “buy” rating on the stock in a report on Wednesday, February 14th. Finally, Stifel Nicolaus boosted their target price on Incyte from $67.00 to $68.00 and gave the stock a “hold” rating in a report on Wednesday, February 14th. Nine investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Incyte presently has a consensus rating of “Moderate Buy” and an average price target of $75.50.

Incyte Trading Down 1.1 %

Incyte stock opened at $51.18 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.36 and a current ratio of 3.55. The business’s 50-day simple moving average is $56.90 and its 200-day simple moving average is $57.73. The firm has a market capitalization of $11.49 billion, a PE ratio of 19.31, a PEG ratio of 1.19 and a beta of 0.65. Incyte has a 52 week low of $50.27 and a 52 week high of $75.74.

Institutional Trading of Incyte

Several hedge funds have recently added to or reduced their stakes in INCY. Cape Investment Advisory Inc. bought a new position in Incyte during the 4th quarter worth about $25,000. Larson Financial Group LLC increased its holdings in Incyte by 4,220.0% during the 4th quarter. Larson Financial Group LLC now owns 432 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 422 shares in the last quarter. Redmont Wealth Advisors LLC bought a new position in Incyte during the 1st quarter worth about $28,000. Riverview Trust Co bought a new position in Incyte during the 1st quarter worth about $29,000. Finally, Turtle Creek Wealth Advisors LLC bought a new position in Incyte during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.